Company Overview

We develop transformative medicines and technologies by building agile, focused companies called Vants.

Why We're Here

Roivant was founded in 2014 with the goal of developing and delivering medicines to patients faster and more efficiently


Roivant has built 20+ portfolio companies (Vants)

Our Vants have conducted 10 Phase 3 trials (9 of which have been successful), and launched VTAMA®, (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults


$3B Upfront Strategic Transaction

In 2019, we consummated a $3B upfront strategic transaction with our partners at Sumitomo Pharma, and we have continued to build a broad and differentiated pipeline of drugs and drug candidates


Diverse leadership and employee base

We have worked to ensure an open, diverse, and inclusive culture, while building a leadership team, board of directors and broader employee base that reflects these values.

Our vant creation Process:

Our vant creation Process
Cellular Background


major clinical catalysts expected in 2023

We have a diverse pipeline of investigational drugs across our family of companies.

For Investors
For Investors

Learn more about our work

Sign up for our latest announcements and upcoming presentations


Advancing medicines that matter

View our broad and differentiated pipeline of investigational drugs.